During the last three months, 22 analysts shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:REGN), revealing diverse outlooks from bullish to bearish. Summarizing their recent ...

Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:REGN) revealed 10 unusual trades. Delving into the details, we found 30% of traders were bullish, while 50% showed bearish ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened ...

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Regeneron provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference.

Fintel reports that on January 16, 2025, UBS downgraded their outlook for Regeneron Pharmaceuticals (WBAG:REGN) from Buy to Neutral. There are 2,500 funds or institutions reporting positions in ...

To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) started 2024 on a strong note and performed well through the first half of the year. However, the drugmaker has since seen its shares decline ...

In the pre-market hours, Regeneron's stock is trading at $695, down 0.27 percent on the Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not ...

(RTTNews) - Regeneron Pharmaceuticals ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...